

SINGAPORE PAINCARE HOLDINGS LIMITED

Company Registration No.: 201843233N
(Incorporated in the Republic of Singapore)

CREDITORS' VOLUNTARY WINDING-UP OF A 51.0% OWNED SUBSIDIARY - APPOINTMENT OF PROVISIONAL LIQUIDATORS

The Board of Directors (the "**Board**") of Singapore Paincare Holdings Limited (the "**Company**") and together with its subsidiaries, the "**Group**") wishes to inform the shareholders of the Company that the directors of its 51.0% owned subsidiary, Dermatology & Laser Specialist Clinic Pte. Ltd. ("**DLS**") had formed the opinion that DLS cannot by reason of its liabilities continue its business and accordingly DLS be wound up voluntarily pursuant to Section 161(1)(b) of the Insolvency, Restructuring and Dissolutions Act 2018 ("**Creditors' Voluntary Winding Up**").

Tan Wei Cheong and Lim Loo Khoo, both of Deloitte Singapore SR&T Restructuring Services Pte Ltd, have been appointed as Joint and Several Provisional Liquidators of DLS on 2 February 2026, upon filing of the Statutory Declaration and the Declaration by Directors of DLS's inability to continue business by reason of its liabilities.

An extraordinary general meeting of DLS's members, as well as a meeting of DLS's creditors, will be convened in due course to vote on the resolutions for the winding up of DLS and to confirm the appointment of Tan Wei Cheong and Lim Loo Khoo as Joint and Several Liquidators of DLS.

The liquidation of DLS is not expected to have any material impact on the net tangible assets or earnings per share of the Company for the current financial year.

Save for their directorship or shareholding interests in the Company and/or DLS, none of the Directors or controlling shareholders of the Company has any interest, direct or indirect, in the Creditor's Voluntary Winding Up of DLS.

The Company will update shareholders should there be any material developments in relation to DLS as and when required. Shareholders are advised to read this announcement and any further announcements by the Company carefully. Shareholders are advised to refrain from taking any action in respect of their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. In the event of any doubt, shareholders should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers.

By Order of the Board

Lee Mun Kam Bernard
Executive Chairman and Chief Executive Officer
3 February 2026

This announcement has been reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**"), and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.